Eli Lilly and Co (XSWX:LLY) Cyclically Adjusted Revenue per Share: CHF31.85 (As of Mar. 2026)


XSWX:LLY Eli Lilly and Co XSWX:LLY
100 GF Score
Price CHF970.00
GF Value CHF1,145.22
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cyclically Adjusted Revenue per Share?

Eli Lilly and Co XSWX:LLY +0.52% 100 Cyclically Adjusted Revenue per Share is CHF31.85 as of Mar. 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,145.22 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share for the three months ended in Mar. 2026 was CHF17.399. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF31.85 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Eli Lilly and Co's average Cyclically Adjusted Revenue Growth Rate was 19.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Eli Lilly and Co was 12.00% per year. The lowest was 1.80% per year. And the median was 7.50% per year.

As of today (2026-07-03), Eli Lilly and Co's current stock price is CHF970.00. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was CHF31.85. Eli Lilly and Co's Cyclically Adjusted PS Ratio of today is 30.46.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eli Lilly and Co was 31.37. The lowest was 3.23. And the median was 9.64.


Eli Lilly and Co  (XSWX:LLY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eli Lilly and Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=970.00/31.85
=30.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eli Lilly and Co was 31.37. The lowest was 3.23. And the median was 9.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Eli Lilly and Co Cyclically Adjusted Revenue per Share Related Terms


Eli Lilly and Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted Revenue per Share Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.82 25.65 25.00 28.83 29.93

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.02 27.76 27.72 29.93 31.85

XSWX:LLY vs JNJ, ABBV, MRK: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.


XSWX:LLY
100GF Score
Eli Lilly and Co XSWX:LLY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=17.399/330.2130*330.2130
=17.399

Current CPI (Mar. 2026) = 330.2130.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 4.943 241.018 6.772
201609 4.763 241.428 6.515
201612 5.519 241.432 7.548
201703 4.957 243.801 6.714
201706 5.334 244.955 7.191
201709 5.157 246.819 6.899
201712 3.086 246.524 4.134
201803 4.482 249.554 5.931
201806 5.367 251.989 7.033
201809 5.007 252.439 6.550
201812 5.475 251.233 7.196
201903 5.178 254.202 6.726
201906 6.023 256.143 7.765
201909 5.906 256.759 7.596
201912 6.562 256.974 8.432
202003 6.166 258.115 7.888
202006 5.743 257.797 7.356
202009 5.763 260.280 7.311
202012 7.229 260.474 9.164
202103 6.935 264.877 8.646
202106 6.721 271.696 8.169
202109 6.862 274.310 8.260
202112 7.959 278.802 9.427
202203 8.008 287.504 9.198
202206 6.972 296.311 7.770
202209 7.475 296.808 8.316
202212 7.517 296.797 8.363
202303 7.131 301.836 7.801
202306 8.291 305.109 8.973
202309 9.496 307.789 10.188
202312 8.949 306.746 9.634
202403 8.621 312.332 9.115
202406 11.173 314.175 11.743
202409 10.709 315.301 11.215
202412 13.359 315.605 13.977
202503 12.489 319.799 12.896
202506 14.060 322.561 14.394
202509 15.590 324.800 15.850
202512 17.118 324.054 17.443
202603 17.399 330.213 17.399

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of CHF31.85 mean?
Eli Lilly and Co (XSWX:LLY) has a Cyclically Adjusted Revenue per Share of CHF31.85 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Cyclically Adjusted Revenue per Share too high?
Eli Lilly and Co's current Cyclically Adjusted Revenue per Share is CHF31.85. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Cyclically Adjusted Revenue per Share compare to JNJ and ABBV?
Eli Lilly and Co's Cyclically Adjusted Revenue per Share of CHF31.85 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Cyclically Adjusted Revenue per Share is CHF31.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,145.22, compared to a current price of CHF970.00 — trading 15.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is CHF31.85. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Cyclically Adjusted Revenue per Share is CHF31.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF970.00 is trading 15.3% below its estimated GF Value™ of CHF1,145.22. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Cyclically Adjusted Revenue per Share: CHF31.85
  • GF Value™: CHF1,145.22 vs. price of CHF970.00 (15.3% below fair value)
  • GF Score™: 100/100 with 6 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score

Get the complete analysis for XSWX:LLY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF970.00
Price
CHF1,145.22
GF Value